Tong Ren Tang Technologies Co. Ltd. (HKG:1666)
3.050
+0.070 (2.35%)
Oct 26, 2026, 4:08 PM HKT
HKG:1666 Revenue
Tong Ren Tang Technologies had revenue of 3.02B CNY in the half year ending June 30, 2026, a decrease of -25.32%. This brings the company's total for the last twelve months to 5.77B, down -16.96% year-over-year. In the year 2025, Tong Ren Tang Technologies had annual revenue of 6.48B, down -10.69%. That makes Tong Ren Tang Technologies the 8,387th largest company in the world by revenue and 515th in Hong Kong.
Revenue (ttm)
5.77B CNY
Revenue Growth
-16.96%
P/S Ratio
0.57
Revenue / Employee
1.52M CNY
Employees
3,801
Market Cap
3.91B HKD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full HKG:1666 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.48B | -775.77M | -10.69% |
| Dec 31, 2024 | 7.26B | 486.18M | 7.18% |
| Dec 31, 2023 | 6.77B | 781.62M | 13.04% |
| Dec 31, 2022 | 5.99B | 591.35M | 10.95% |
| Dec 31, 2021 | 5.40B | 793.12M | 17.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 48.06B |
| WuXi Biologics | 27.27B |
| Hansoh Pharmaceutical Group Company | 18.35B |
| Innovent Biologics | 18.13B |
| China Isotope & Radiation | 8.44B |
| Qyuns Therapeutics | 1.18B |
| Ocumension Therapeutics | 1.08B |
| Jacobio Pharmaceuticals Group | 852.85M |
Tong Ren Tang Technologies News
- 8 months ago - Chinese Medicine Firm Seeks Elusive Elixir Of IPO Success - Benzinga